- A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
- Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, Wu HT, Balcioglu M, Sethi H, Scott D, Foran J, McMillan A, Ford JM, Telli ML.
- Nat Cancer. 2022 Oct 17. doi: 10.1038/s43018-022-00439-1. Epub ahead of print.
- PMID: 36253484
- PubMed abstract
Identifier: NCT02401347: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Oct 18.)
Identifier: NCT04756765: Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 18.)
- Polygenic Risk Scores Could Refine Breast Cancer Screening Recommendations.
- Curtin C.
- Precision Oncology News. 2022 Oct 17.
- Research news